

## Special Issue

# Treatment of Hepatopancreatobiliary Cancers: Open Question, Challenge, and Future Directions (2nd Edition)

### Message from the Guest Editors

Rates of hepatopancreatobiliary (HPB) malignancies are increasing. Surgery is the cornerstone of treatment. However, only marginal improvements in patient survival have been achieved over the past few decades. The anatomical localisation of tumours in the vicinity of critical vascular structures, disease diffusion (e.g., peritoneal carcinomatosis, oligometastatic disease), and aggressive tumour biology are often responsible for poor outcomes. Recently, more aggressive approaches have been adopted, including extensive vascular resection, neoadjuvant treatments, and locoregional therapies. Liver transplantation (LT) is a well-recognised hepatocellular carcinoma (HCC) treatment and is increasingly being used in cholangiocarcinoma and colorectal liver metastases. Minimally invasive and ablative therapies are adjuncts or even replacements for resection. More recently, artificial intelligence in HPB surgery has shown promising implications in diagnosis and targeted treatment.

This Special Issue will focus on these extended indications and novel therapeutic approaches, as they are vital for improving the prognosis of these detrimental malignancies.

---

### Guest Editors

Dr. Francesco Giovinazzo

General Surgery and Organ Transplantation Unit, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy

Dr. Stijn van Laarhoven

Department of HPB Surgery, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK

---

### Deadline for manuscript submissions

closed (30 September 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/223875](https://mdpi.com/si/223875)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)